Bonilla Palomas, Juan LuisGamez Lopez, Antonio LuisMoreno Conde, MirianLopez Ibanez, Maria CristinaMoreno Villar, Maria Amparo2025-01-072025-01-072021-09-010212-1611https://hdl.handle.net/10668/26573Introduction: inflammatory activity (IA) is a cause of hypoalbuminemia in patients with acute heart failure (AHF).Objectives: the main objective of this study was to evaluate whether an AI modulator treatment contributes to correcting albuminemia in this context.Methods: in this clinical trial 43 patients with AHF, hypoalbuminemia (serum albumin = 25 mg/l] were randomly assigned to receive omega-3 fatty acids (4 g daily) or placebo for 4 weeks. Albuminemia and CRP were reassessed at weeks 1 and 4. An analysis of variance for repeated measures was performed.Results: mean age was 75.6 +/- 8.8 years, 72.1 % were male, and the most frequent etiology was ischemic (46.5 %). The two groups were homogeneous in their baseline characteristics. A significant increase in albumin concentration was found at week 4 from baseline (p for the effect of timeesAttribution-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-sa/4.0/Heart failureHypoalbuminemiaInflammatory activityOmega-3 polyunsaturated fatty acidsClinical trialPolyunsaturated fatty-acidsLevels predict survivalNecrosis-factor-alphaSerum-albuminEuropean-societyProteinActivationReceptorsMortalityDiagnosisresearch article34154367open access10.20960/nh.036371699-5198https://www.nutricionhospitalaria.org/filesPortalWeb/27/MA-00027-01.pdf?uMNu82MMWoDsb55gx9B04pEeObqNSrZX754885100002